Comparison of the therapeutic efficacy of benzalkonium bromide, pirarubicin, and mitomycin C in prevention of postoperative recurrence of superficial bladder cancer / 肿瘤

ABSTRACT

Objective: To compare the effectiveness and safety of bladder instillation of bzalkonium bromide (BR), pirarubicin (THP), or mitomycin C (MMC) in prevention of postoperative recurrence of superficial bladder transient cell carcinoma (SBTCC). Methods: One hundred and twenty-seven patients with SBTCC who underwent transurethral resection of bladder tumor (TURBt) or partial cystectomy were randomly divided into 3 groups. BA group (n = 43) received intravesical instillation of 0.1% BB 300 mL and retained for 15 min for one time. THP group (n = 42) received intravesical instillation of 30 mg THP in 50 mL of 0.9% NaCl solution. MMC group (n = 42) received intravesical instillation of 40 mg MMC in 50 mL of 0.9% NaCl solution. THP and MMC were given to patients once a week for 8 weeks and then once a month for one year. All the patients were followed up and received cystoscopy examination. The recurrence rate and side effects were compared between the three groups. Results: All patients were followed up for 24 months. The tumor recurrent rates were 4.7%, 23.8%, and 26.2% in BB, THP, and MMC groups, respectively. The tumor recurrence rate of BB group was significantly lower than that in THP and MMC groups (P 0.05). The pathological grade, clinical staging, primary and recurrent tumors, and different instillation drug therapies had significant effects on the recurence rate (P 0.05). Conclusion: Postoperative intravesical administration of BB is more effective than THP and MMC with well toleration and low cost. No apparent side effects are observed.